The form is not published.

Heading

Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.

Epcoritamab-bysp in Combination with Rituximab and Lenalidomide Approved as Treatment Option for Relapsed or Refractory Follicular Lymphoma in the U.S.

On November 18, 2025, the FDA approved epcoritamab-bysp (EPKINLY®) in combination with rituximab and lenalidomide for adults with relapsed or ...
/
Unlock the Cure Gala 2025 Raises Funds for Vital Research

Unlock the Cure Gala 2025 Raises Funds for Vital Research

The Unlock the Cure Gala 2025 brought supporters together to fund vital research and deliver hope for people living with ...
/
Choosing Your Next Treatment: What FL (follicular lymphoma) Patients Should Know

Choosing Your Next Treatment: What FL (follicular lymphoma) Patients Should Know

Watch this webinar from November 2025 where the panel discusses and shares insights on what matters most to doctors and ...
/
Living Well with Follicular Lymphoma: Understanding Watch & Wait (Active Monitoring)

Living Well with Follicular Lymphoma: Understanding Watch & Wait (Active Monitoring)

This free webinar was open to all and featured expert discussion and lived experience on the topic of Watch & ...
/
Nicolas’s Story

Nicolas’s Story

My name is Nicolas, and I am from Omaha, Nebraska in the United States. I am at stage 3 FL ...
/
follicular_lymphoma_Hero1-min

Finding a Clinical Trial: Dr. Mitchell Smith, FLF Chief Medical Officer, Provides Expert Advice on Your Important Questions

In this Q&A, Dr. Mitchell Smith dives into common questions on how to find and join a clinical trial, helping ...
/